What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?

Artigo Revisado por pares

What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?

1996; Wiley; Volume: 6; Issue: 2 Linguagem: Inglês

10.1002/(sici)1099-1654(199606)6

ISSN

1099-1654

Autores

Erik De Clercq,

Tópico(s)

HIV/AIDS Research and Interventions

Resumo

Reviews in Medical VirologyVolume 6, Issue 2 p. 97-117 Research Article What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections? Erik De Clercq, Erik De Clercq Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, BelgiumSearch for more papers by this author Erik De Clercq, Erik De Clercq Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, BelgiumSearch for more papers by this author First published: June 1996 https://doi.org/10.1002/(SICI)1099-1654(199606)6:2 3.0.CO;2-4Citations: 55AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 de Clercq, E., (1995) Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8, 200–239. PubMedWeb of Science®Google Scholar 2 de Clercq, E., (1995) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38, 2491–2517. 10.1021/jm00014a001 CASPubMedWeb of Science®Google Scholar 3 de Clercq, E., (1995) Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5, 149–164. 10.1002/rmv.1980050305 CASWeb of Science®Google Scholar 4 Naesens, L., Balzarini, J. and de Clercq, E., (1994) Therapeutic potential of PMEA as an antiviral drug. Rev. Med. Virol. 4, 147–159. 10.1002/rmv.1980040302 Web of Science®Google Scholar 5 Balzarini, J., Holy, A., Jindrich, J., et al. (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37, 332–338. 10.1128/AAC.37.2.332 CASPubMedWeb of Science®Google Scholar 6 Tsai, C.-C., Follis, K. E., Sabo, A., et al. (1995) Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270, 1197–1199. 10.1126/science.270.5239.1197 CASPubMedWeb of Science®Google Scholar 7 de Clercq, E., (1993) HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13, 229–258. 10.1002/med.2610130303 CASPubMedWeb of Science®Google Scholar 8 de Clercq, E., (1994) Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Exp. Opin. Invest. Drugs 3, 253–271. 10.1517/13543784.3.3.253 CASGoogle Scholar 9 Baba, M., Tanaka, H., De Clercq, E., et al. (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 165, 1375–1381. 10.1016/0006-291X(89)92756-3 CASPubMedWeb of Science®Google Scholar 10 Miyasaka, T., Tanaka, H., Baba, M., et al. (1989) A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32, 2507–2509. 10.1021/jm00132a002 CASPubMedWeb of Science®Google Scholar 11 Pauwels, R., Andries, K., Desmyter, J., et al. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470–474. 10.1038/343470a0 CASPubMedWeb of Science®Google Scholar 12 Debyser, Z., Pauwels, R., Andries, K., et al. (1991) An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives. Proc. Natl Acad. Sci. USA 88, 1451–1455. 10.1073/pnas.88.4.1451 CASPubMedWeb of Science®Google Scholar 13 Baba, M., De Clercq, E., Tanaka, H., et al. (1991) Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl Acad. Sci. USA 88, 2356–2360. 10.1073/pnas.88.6.2356 CASPubMedWeb of Science®Google Scholar 14 Baba, M., De Clercq, E., Tanaka, H., et al. (1991) Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol. Pharmacol. 39, 805–810. CASPubMedWeb of Science®Google Scholar 15 Merluzzi, V. J., Hargrave, K. D., Labadia, M., et al. (1990) Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 250, 1411–1413. 10.1126/science.1701568 CASPubMedWeb of Science®Google Scholar 16 Koup, R. A., Merluzzi, V. J., Hargrave, K. D., et al. (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J. Infect. Dis. 163, 966–970. 10.1093/infdis/163.5.966 CASPubMedWeb of Science®Google Scholar 17 Goldman, M. E., Nunberg, J. H., O'Brien, J. A., et al. (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl Acad. Sci. USA 88, 6863–6867. 10.1073/pnas.88.15.6863 CASPubMedWeb of Science®Google Scholar 18 Goldman, M. E., O'Brien, J. A., Ruffing, T. L., et al. (1992) L.-696, 229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob. Agents Chemother. 36, 1019–1023. 10.1128/AAC.36.5.1019 CASPubMedWeb of Science®Google Scholar 19 Romero, D. L., Busso, M., Tan, C.-K., et al. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl Acad. Sci. USA 88, 8806–8810. 10.1073/pnas.88.19.8806 CASPubMedWeb of Science®Google Scholar 20 Romero, D. L., Morge, R. A., Genin, M. J., et al. (1993) Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino] pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 36, 1505–1508. 10.1021/jm00062a027 CASPubMedWeb of Science®Google Scholar 21 Balzarini, J., Pérez-Pérez, M.-J., San-Félix, A., et al. (1992) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl Acad. Sci. USA 89, 4392–4396. 10.1073/pnas.89.10.4392 CASPubMedWeb of Science®Google Scholar 22 Balzarini, J., Pérez-Pérez, M.-J., San-Félix, A., Vélazquez, S., Camarasa, M.-J. and de Clercq, E., (1992) [2′,5′-Bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 36, 1073–1080. 10.1128/AAC.36.5.1073 CASPubMedWeb of Science®Google Scholar 23 Balzarini, J., Pérez-Pérez, M.-J., San-Félix, A., et al. (1992) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1 specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO-T). J. Biol. Chem. 267, 11831–11838. CASPubMedWeb of Science®Google Scholar 24 Pauwels, R., Andries, K., Debyser, Z., et al. (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl Acad. Sci. USA 90, 1711–1715. 10.1073/pnas.90.5.1711 CASPubMedWeb of Science®Google Scholar 25 de Clercq, E., (1996) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev., 16, 125–157. 10.1002/(SICI)1098-1128(199603)16:2 3.0.CO;2-2 CASPubMedWeb of Science®Google Scholar 26 White, E. L., Buckheit, R. W., Jr., Ross, L. J., et al. (1991) A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer techniques. Antiviral Res. 16, 257–266. 10.1016/0166-3542(91)90005-C CASPubMedWeb of Science®Google Scholar 27 Pauwels, R., Andries, K., Debyser, Z., et al. (1994) New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob. Agents Chemother. 38, 2863–2870. 10.1128/AAC.38.12.2863 CASPubMedWeb of Science®Google Scholar 28 Baba, M., Yuasa, S., Niwa, T., et al. (1993) Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochem. Pharmacol. 45, 2507–2512. 10.1016/0006-2952(93)90232-L CASPubMedWeb of Science®Google Scholar 29 Yuasa, S., Sadakata, Y., Takashima, H., et al. (1993) Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol. Pharmacol. 44, 895–900. CASPubMedWeb of Science®Google Scholar 30 Baba, M., Shigeta, S., Yuasa, S., et al. (1994) Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38, 688–692. 10.1128/AAC.38.4.688 CASPubMedWeb of Science®Google Scholar 31 Hargrave, K. D., Proudfoot, J. R., Grozinger, K. G., et al. (1991) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J. Med. Chem. 34, 2231–2241. 10.1021/jm00111a045 CASPubMedWeb of Science®Google Scholar 32 Saari, W. S., Hoffman, J. M., Wai, J. S., et al. (1991) 2-Pyridinone derivatives: a new class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors. J. Med. Chem. 34, 2922–2925. 10.1021/jm00113a036 CASPubMedWeb of Science®Google Scholar 33 Dueweke, T. J., Poppe, S. M., Romero, D. L., et al. (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37, 1127–1131. 10.1128/AAC.37.5.1127 CASPubMedWeb of Science®Google Scholar 34 Camarasa, M.-J., Pérez-Pérez, M.-J., San-Félix, A., Balzarini, J. and de Clercq, E., (1992) 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type inhibitors: synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo- and -ribofuranose]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) pyrimidine nucleosides. J. Med. Chem. 35, 2721–2727. 10.1021/jm00093a002 CASPubMedWeb of Science®Google Scholar 35 Pérez-Pérez, M.-J., San-Félix, A., Balzarini, J., De Clercq, E. and Camarasa, M. J., (1992) TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 35, 2988–2995. 10.1021/jm00094a009 CASPubMedWeb of Science®Google Scholar 36 Ahgren, C., Bäckbro, K., Bell, F. W., et al. (1995) The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39, 1329–1335. 10.1128/AAC.39.6.1329 CASPubMedWeb of Science®Google Scholar 37 Zhang, H., Vrang, L., Bäckbro, K., et al. (1995) Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res. 28, 331–342. 10.1016/0166-3542(95)00056-9 CASPubMedWeb of Science®Google Scholar 38 Bader, J. P., McMahon, J. B., Schultz, R. J., et al. (1991) Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl Acad. Sci. USA 88, 6740–6744. 10.1073/pnas.88.15.6740 CASPubMedWeb of Science®Google Scholar 39 Balzarini, J., Jonckheere, H., Harrison, W. A., et al. (1995) Oxathiin carboxanilide derivatives: a class of non-nucleoside HIV-1 specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem. Chemother. 6, 169–178. 10.1177/095632029500600306 CASWeb of Science®Google Scholar 40 Balzarini, J., Brouwer, W. G., Felauer, E. E., De Clercq, E. and Karlsson, A., (1995) Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res. 27, 219–236. 10.1016/0166-3542(95)00006-8 CASPubMedWeb of Science®Google Scholar 41 Balzarini, J., Pelemans, H., Aquaro, S., Perno, C.-F., Witvrouw, M., Schols, D., De Clercq, E. and Karlsson, A., (1996) Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Mol. Pharmacol., in press. Google Scholar 42 Kleim, J.-P., Bender, R., Billhardt, U.-M., et al. (1993) Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37, 1659–1664. 10.1128/AAC.37.8.1659 CASPubMedWeb of Science®Google Scholar 43 Kleim, J.-P., Bender, R., Kirsch, R., et al. (1995) Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 39, 2253–2257. 10.1128/AAC.39.10.2253 CASPubMedWeb of Science®Google Scholar 44 Buckheit, R. W., Jr., Hollingshead, M. G., Germany-Decker, J., et al. (1993) Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 21, 247–265. 10.1016/0166-3542(93)90031-D CASPubMedWeb of Science®Google Scholar 45 Mertens, A., Zilch, H., König, B., et al. (1993) Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo [2,3a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity. J. Med. Chem. 36, 2526–2535. 10.1021/jm00069a011 CASPubMedWeb of Science®Google Scholar 46 Maass, G., Immendoerfer, U., Koenig, B., et al. (1993) Viral resistance to the thiazolo-isoindolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37, 2612–2617. 10.1128/AAC.37.12.2612 CASPubMedWeb of Science®Google Scholar 47 Williams, T. M., Ciccarone, T. M., MacTough, S. C., et al. (1993) 5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J. Med. Chem. 36, 1291–1294. 10.1021/jm00061a022 CASPubMedWeb of Science®Google Scholar 48 Dollé, V., Nguyen, C. H., Aubertin, A.-M., et al. (1995) A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J. Med. Chem. 38, 4679–4686. 10.1021/jm00023a007 CASPubMedWeb of Science®Google Scholar 49 Artico, M., Massa, S., Mai, A., et al. (1993) 3,4-Dihydro-2-alkoxy-6-benyzl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 4, 361–368. 10.1177/095632029300400608 CASWeb of Science®Google Scholar 50 Massa, S., Mai, A., Artico, M., et al. (1995) Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 6, 1–8. 10.1177/095632029500600101 CASWeb of Science®Google Scholar 51 Buckheit, R. W., Jr., Fliakas-Boltz, V., Decker, W. D., et al. (1994) Biological and biochemical anti-HIV activity of the benzothiadiazine class of non-nucleoside reverse transcriptase inhibitors. Antiviral Res. 25, 43–56. 10.1016/0166-3542(94)90092-2 CASPubMedWeb of Science®Google Scholar 52 Tucker, T. J., Lyle, T. A., Wiscount, C. M., et al. (1994) Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2 (1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 37, 2437–2444. 10.1021/jm00041a023 CASPubMedWeb of Science®Google Scholar 53 Ijichi, K., Fujiwara, M., Hanasaki, Y., et al. (1995) Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives. Antimicrob. Agents Chemother. 39, 2337–2340. 10.1128/AAC.39.10.2337 CASPubMedWeb of Science®Google Scholar 54 Bellarosa, D., Antonelli, G., Bambacioni, F., et al. (1996) New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res., in press. Google Scholar 55 Kashman, Y., Gustafson, K. R., Fuller, R. W., et al. (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree Calophyllum lanigernum. J. Med. Chem. 35, 2735–2743. 10.1021/jm00093a004 CASPubMedWeb of Science®Google Scholar 56 Patil, A. D., Freyer, A. J., Eggleston, D. S., et al. (1993) The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum linn. J. Med. Chem. 36, 4131–4138. 10.1021/jm00078a001 CASPubMedWeb of Science®Google Scholar 57 de Lucca, G. V. and Otto, M. J., (1992) Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-ones. Bioorg. Med. Chem. Lett. 2, 1639–1644. 10.1016/S0960-894X(00)80447-3 CASWeb of Science®Google Scholar 58 Terrett, N. K., Bojanic, D., Merson, J. R., et al. (1992) Imidazo[2′,3′:6,5]dipyrido[3,2-b:2′,3′-e]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine. Bioorg. Med. Chem. Lett. 2, 1745–1750. 10.1016/S0960-894X(00)80468-0 CASWeb of Science®Google Scholar 59 Livermore, D. G. H., Bethell, R. C., Cammack, N., et al. (1993) Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines. J. Med. Chem. 36, 3784–3794. 10.1021/jm00076a005 CASPubMedWeb of Science®Google Scholar 60 Antonucci, T., Warmus, J. S., Hodges, J. C. and Nickell, D. G., (1995) Characterization of the antiviral activity of highly substituted pyrroles: a novel class of non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem. Chemother. 6, 98–108. 10.1177/095632029500600204 CASWeb of Science®Google Scholar 61 McMahon, J. B., Gulakowski, R. J., Weislow, O. S., et al. (1993) Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37, 754–760. 10.1128/AAC.37.4.754 CASPubMedWeb of Science®Google Scholar 62 Alam, M., Bechtold, C. M., Patick, A. K., et al. (1993) Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors. Antiviral Res. 22, 131–141. 10.1016/0166-3542(93)90091-V CASPubMedWeb of Science®Google Scholar 63 Artico, M., Stefancich, G., Silvestri, R., et al. (1994) Pyrrolobenzothiazepines: a new class of non-nucleoside HIV-1 reverse transcriptase inhibitors. Med. Chem. Res. 4, 283–290. CASGoogle Scholar 64 Mui, P. W., Jacober, S. P., Hargrave, K. D. and Adams, J., (1992) Crystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase and computational alignment with a structurally diverse inhibitor. J. Med. Chem. 35, 201–202. 10.1021/jm00079a029 CASPubMedWeb of Science®Google Scholar 65 Chimirri, A., Grasso, S., Monforte, A. M., Monforte, P. and Zappalà, M., (1995) Thiazobenzimidazoles as non-nucleoside HIV-1 RT inhibitors. Abstracts of the II Congresso Congiunto Italiano-Spagnolo di Chimica Farmaceutica, Ferrara, Italy, August 30–September 3, 1995, ML20. Google Scholar 66 Ren, J., Esnouf, R., Hopkins, A., et al. (1995) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 3, 915–926. 10.1016/S0969-2126(01)00226-X CASPubMedWeb of Science®Google Scholar 67 Kroeger-Smith, M. B., Rouzer, C. A., Taneyhill, L. A., et al. (1995) Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Sci. 4, 2203–2222. 10.1002/pro.5560041026 CASPubMedGoogle Scholar 68 Ding, J., Das, K., Tantillo, C., et al. (1995) Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R95845 at 2.8 Å resolution. Structure 3, 365–379. 10.1016/S0969-2126(01)00168-X CASPubMedWeb of Science®Google Scholar 69 Ding, J., Das, K., Moereels, H., et al. (1995) Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Structural Biol. 2, 407–415. 10.1038/nsb0595-407 CASPubMedWeb of Science®Google Scholar 70 Tramontano, E. and Cheng, Y.-C., (1992) HIV-1 reverse transcriptase inhibition by a dipyrido-diazepinone derivative: BI-RG-587. Biochem. Pharmacol 43, 1371–1376. 10.1016/0006-2952(92)90515-K CASPubMedWeb of Science®Google Scholar 71 Althaus, I. W., Chou, J. J., Gonzales, A. J., et al. (1993) Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J. Biol. Chem. 268, 6119–6124. CASPubMedWeb of Science®Google Scholar 72 Frank, K. B., Noll, G. J., Connell, E. V. and Sim, I. S., (1991) Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]benzodiazepine-2-(1H)-thione compound, R82150. J. Biol. Chem. 266, 14232–14236. CASPubMedWeb of Science®Google Scholar 73 Kopp, E. B., Miglietta, J. J., Shrutkowski, A. G., Shih, C.-K., Grob, P. M. and Skoog, M. T., (1991) Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template. Nucleic Acids Res. 19, 3035–3039. 10.1093/nar/19.11.3035 CASPubMedWeb of Science®Google Scholar 74 Debyser, Z., Vandamme, A.-M., Pauwels, R., Baba, M., Desmyter, J. and de Clercq, E., (1992) Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2′,3′-dideoxynucleoside 5′-triphosphate, tetrahydro-imidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-thymine derivatives. J. Biol. Chem. 267, 11769–11776. CASPubMedWeb of Science®Google Scholar 75 Debyser, Z., Pauwels, R., Andries, K., et al. (1992) Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds. Mol Pharmacol. 41, 203–208. CASPubMedWeb of Science®Google Scholar 76 Wu, J. C., Warren, T. C., Adams, J., et al. (1991) A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 30, 2022–2026. 10.1021/bi00222a003 CASPubMedWeb of Science®Google Scholar 77 Debyser, Z., Pauwels, R., Baba, M., Desmyter, J. and de Clercq, E., (1992) Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase. Mol Pharmacol. 41, 963–968. CASPubMedWeb of Science®Google Scholar 78 Debyser, Z., De Vreese, K., Pauwels, R., et al. (1992) Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus. J. Gen. Virol. 73, 1799–1804. 10.1099/0022-1317-73-7-1799 CASPubMedWeb of Science®Google Scholar 79 Spence, R. A., Kati, W. M., Anderson, K. S. and Johnson, K. A., (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267, 988–993. 10.1126/science.7532321 CASPubMedWeb of Science®Google Scholar 80 Cohen, K. A., Hopkins, J., Ingraham, R. H., et al. (1991) Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J. Biol. Chem. 266, 14670–14674. CASPubMedWeb of Science®Google Scholar 81 Shih, C.-K., Rose, J. M., Hansen, G. L., Wu, J. C., Bacolla, A. and Griffin, J. A., (1991) Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptase display reversed sensitivity to non-nucleoside analog inhibitors. Proc. Natl Acad. Sci. USA 88, 9878–9882. 10.1073/pnas.88.21.9878 CASPubMedWeb of Science®Google Scholar 82 de Vreese, K., Debyser, Z., Vandamme, A.-M., et al. (1992) Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology 188, 900–904. 10.1016/0042-6822(92)90550-9 CASPubMedWeb of Science®Google Scholar 83 Condra, J. H., Emini, E. A., Gotlib, L., et al. (1992) Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob. Agents Chemother. 36, 1441–1446. 10.1128/AAC.36.7.1441 CASPubMedWeb of Science®Google Scholar 84 Hizi, A., Shaharabany, M., Currens, M. J., Boyd, M. R., Hughes, S. H. and McMahon, J. B., (1993) Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37, 1037–1042. 10.1128/AAC.37.5.1037 CASPubMedWeb of Science®Google Scholar 85 Arnold, E., Jacobo-Molina, A., Nanni, R. G., et al. (1992) Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locations. Nature 357, 85–89. 10.1038/357085a0 CASPubMedWeb of Science®Google Scholar 86 Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. and Steitz, T. A., (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783–1790. 10.1126/science.1377403 CASPubMedWeb of Science®Google Scholar 87 Jacobo-Molina, A., Ding, J., Nanni, R. G., et al. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl Acad. Sci. USA 90, 6320–6324. 10.1073/pnas.90.13.6320 CASPubMedWeb of Science®Google Scholar 88 Unge, T., Knight, S., Bhikhabhai, R., et al. (1994) 2.2. Å resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm sub-domains). Structure 2, 953–961. 10.1016/S0969-2126(94)00097-2 CASPubMedWeb of Science®Google Scholar 89 Ren, J., Esnouf, R., Garman, E., et al. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Structural Biol. 2, 293–302. 10.1038/nsb0495-293 CASPubMedWeb of Science®Google Scholar 90 Nanni, R. G., Ding, J., Jacobo-Molina, A., Hughes, S. H. and Arnold, E., (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspect. Drug Discov. Design 1, 129–150. 10.1007/BF02171659 CASGoogle Scholar 91 Tantillo, C., Ding, J., Jacobo-Molina, A., et al. (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243, 369–387. 10.1006/jmbi.1994.1665 CASPubMedWeb of Science®Google Scholar 92 Esnouf, R., Ren, J., Ross, C., Jones, Y., Stammers, D. and Stuart, D., (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Structural Biol. 2, 303–308. 10.1038/nsb04

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?